We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.50
Bid: 14.00
Ask: 15.00
Change: 0.50 (3.57%)
Spread: 1.00 (7.143%)
Open: 14.00
High: 15.00
Low: 14.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

Thu, 04th Jan 2024 16:54

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

The FTSE 100 index closed up 40.74 points, 0.5%, at 7,723.07. The FTSE 250 ended up 45.65 points, 0.2%, at 19,372.05, and the AIM All-Share closed up 1.79 points, or 0.2%, at 755.94.

The Cboe UK 100 ended up 0.6% at 771.71, the Cboe UK 250 closed up 0.6% at 16,874.97, and the Cboe Small Companies ended up 0.5% at 14,940.05.

Stocks in New York were higher at the London equities close, with the DJIA up 0.7%, the S&P 500 index up 0.4%, and the Nasdaq Composite up 0.2%.

Since the new year, eyes have been on the US economy and where interest rates may go in 2024.

On Wednesday evening, investors had the minutes from the latest US Federal Reserve meeting, back in December.

At the December meeting, the rate-setting Federal Open Market Committee agreed to hold its benchmark rate steady in a range between 5.25% and 5.5%. Members indicated that they expect three quarter-percentage point cuts by the end of 2024.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the highly anticipated minutes stated.

Officials "reaffirmed that it would be appropriate for policy to remain at a restrictive stance for some time until inflation was clearly moving down sustainably."

On Thursday, focus has been on the health of the US labour market.

The US labour market added more jobs than expected in December, according to a tracker from payroll processing firm ADP.

ADP said sector employment increased by 164,000 jobs in December, picking up from a 101,000 rise in November and ahead of the FXStreet cited consensus of 115,000. The November total of jobs added was revised from 103,000 to 101,000.

Meanwhile, US new jobless claims fell by more than expected in the most recent week.

According to the US Department of Labor, new jobless claims totalled 202,000 in the week ended December 30. This is down from last week's revised level of 220,000. The latest reading came in lower than FXStreet-cited consensus of 216,000.

The data is out ahead of the US nonfarm payrolls Friday.

Meanwhile, in European equities on Thursday, the CAC 40 in Paris and the DAX 40 in Frankfurt both ended up 0.5%.

According to Destatis, Germany's annual inflation picked up to 3.7%, from 3.2% in November. This came in slightly behind FXStreet market consensus of 3.8%.

Capital Economics' Andrew Kenningham commented: "The jump in Germany's headline inflation rate in December came as no surprise as it was driven by energy price subsidies introduced more than a year ago. With core inflation continuing to trend down, it should not affect investors' expectations for the [European Central Bank] to begin cutting interest rates in the coming months."

The pound was quoted at USD1.2696 at the London equities close Thursday, up compared to USD1.2646 at the close on Wednesday. The euro stood at USD1.0961 at the European equities close Thursday, higher against USD1.0915 at the same time on Wednesday. Against the yen, the dollar was trading at JPY144.48, up compared to JPY143.50 late Wednesday.

In the FTSE 100, retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

JD Sports Fashion plummeted 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

Next rose 5.5%, on the back of its trading update.

"Clothing retailer Next has set the bar high for the rest of the retail sector by posting a strong trading update this morning," Edison analyst Russell Pointon commented.

In the nine weeks to December 30, the clothing and homewares seller's full price sales were 5.7% higher year-on-year, some GBP38 million better than its previous guidance. It had expected growth of 2.0% year-on-year. The period forms part of its fourth quarter, which concludes on January 27.

The company now expects pretax profit for financial 2024 of GBP905 million, a lift of GBP20 million from its previous outlook, and it would represent a year-on-year increase of 4.0%. Next had initially expected pretax profit of GBP795 million, but it has, now on a number of occasions, lifted its bottom line outlook.

Meanwhile, BP and Shell rose 0.5% and 0.2%, respectively, as oil prices extended their recent upward movements on concerns over the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell's investment director Russ Mould explained.

Brent oil was quoted at USD76.60 a barrel at the London equities close Thursday, down from USD78.13 late Wednesday. Over the last week the price has hit highs of USD79.83.

On London's AIM, Angle shares more than doubled to 31.40 pence.

The Surrey-based medical diagnostics provider celebrated "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Gold was quoted at USD2,0445.01 an ounce at the London equities close Thursday, up against USD2,038.89 at the close on Wednesday.

In Friday's UK corporate calendar, MTI Wireless Edge will hold its extraordinary general meeting regarding proposed grant of options to the directors.

The economic calendar for Friday has eurozone inflation readings at 1000 GMT. Before that, there is the UK Halifax house price index at 0700 GMT.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.